Search research articles
Contact Us
Filters
Showing results (161-170 of 181) with videos related to
Page
of 19
Sort By:
The Lancet. Diabetes & Endocrinology
|
May 30, 2018
Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial
Martin Schlumberger, Sophie Leboulleux, Bogdan Catargi, et al.
ESMO Open
|
November 28, 2024
Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study
N Girard, F Guisier, A Swalduz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 12, 2021
Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR
Christelle de la Fouchardière, Yann Godbert, Cécile Dalban, et al.
Frontiers in Endocrinology
|
July 17, 2024
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)
Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2021
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
Lori J Wirth, Marcia S Brose, Eric J Sherman, et al.
Thyroid : Official Journal of the American Thyroid Association
|
March 30, 2017
Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases
Benjamin Bonhomme, Yann Godbert, Gaelle Perot, et al.
Frontiers in Veterinary Science
|
August 22, 2022
Welfare issues and potential solutions for laying hens in free range and organic production systems: A review based on literature and interviews
Claire Bonnefous, Anne Collin, Laurence A Guilloteau, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 23, 2021
Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study
Marion Panhaleux, Olivier Espitia, Benjamin Terrier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 19, 2023
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer
Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud, et al.
Trials
|
July 11, 2023
Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial
Dana Hartl, Yann Godbert, Xavier Carrat, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 181) with videos related to
Sort By:
Page
of 19
The Lancet. Diabetes & Endocrinology
|
May 30, 2018
Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial
Martin Schlumberger, Sophie Leboulleux, Bogdan Catargi, et al.
ESMO Open
|
November 28, 2024
Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study
N Girard, F Guisier, A Swalduz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 12, 2021
Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR
Christelle de la Fouchardière, Yann Godbert, Cécile Dalban, et al.
Frontiers in Endocrinology
|
July 17, 2024
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)
Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2021
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
Lori J Wirth, Marcia S Brose, Eric J Sherman, et al.
Thyroid : Official Journal of the American Thyroid Association
|
March 30, 2017
Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases
Benjamin Bonhomme, Yann Godbert, Gaelle Perot, et al.
Frontiers in Veterinary Science
|
August 22, 2022
Welfare issues and potential solutions for laying hens in free range and organic production systems: A review based on literature and interviews
Claire Bonnefous, Anne Collin, Laurence A Guilloteau, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 23, 2021
Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study
Marion Panhaleux, Olivier Espitia, Benjamin Terrier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 19, 2023
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer
Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud, et al.
Trials
|
July 11, 2023
Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial
Dana Hartl, Yann Godbert, Xavier Carrat, et al.
Page
of 19